| Literature DB >> 35377025 |
Usama Nasir1, Tayyab Ali Waheed2, Keerat Rai Ahuja2, Charnjeet Singh Sandhu2, Muhammad Ameen2, Earl J Hope3.
Abstract
Entities:
Year: 2022 PMID: 35377025 PMCID: PMC8980178 DOI: 10.1186/s43044-022-00262-0
Source DB: PubMed Journal: Egypt Heart J ISSN: 1110-2608
Baseline study characteristics
| Study | LTS ( | RTS ( | Definition of RTS and LTS | Key inclusion criteria | Key exclusion criteria | Types of ACS | Follow-up duration | Outcomes of interest |
|---|---|---|---|---|---|---|---|---|
| Cooper et al./CRIT 2011 [4] | 21 | 24 | LTS: hematocrit < 30% with post-transfusion goal of 30–33% RTS: hematocrit < 24% with post-transfusion goal 24–27% | AMI (ischemic-type chest discomfort lasting ≥ 30 min and associated with a creatine kinase-MB (CK-MB) or cardiac troponin level above the upper limit of normal. Hematocrit ≤ 30% within 72 h of symptom onset | Age < 21; non-coronary cause for clinical syndrome; active bleeding; RBC transfusion within 7 days of enrollment; imminent death; pregnancy | STE/NSTE | 1 month | All-cause mortality; in-hospital mortality; recurrent MI/ACS, 30-day mortality |
| Carson et al. 2013 [5] | 55 | 55 | LTS: < 10 g/dl with post-transfusion goal > 10 g/dl RTS: < 8 g/dl or symptomatic for post-transfusion goal > 8 g/dl | Age ≥ 18; STEMI, NSTEMI, unstable angina, stable CAD undergoing cardiac catheterization; Hb < 10 g/dl at the time of random allocation | Hgb > 10; symptoms of anemia at the time of randomization; cardiac surgery within 30 days; severe illness; Ventilated/intubated; hemodynamic instability | STE/NSTE/stable angina | 1 month | All-cause mortality; in-hospital mortality; recurrent MI/ACS; 30-day mortality |
| Ducrocq et al. 2021/REALITY [6] | 324 | 342 | LTS: ≤ 10 g/dl, with post-transfusion goal ≥ 11 g/dl RTS: ≤ 8 g/dl, with post-transfusion goal 8–10 g/dl | Age ≥ 18; AMI (with or without ST-segment elevation with a combination of ischemic symptoms occurring in the 48 h before admission and elevation of biomarkers, and Hb 7–10 g/dl | Shock; MI occurring after PCI or CABG; life-threatening or massive ongoing bleeding; blood transfusion in the past 30 days; malignant hematologic disease | STE/NSTE | 1 month | All-cause mortality; in-hospital mortality; recurrent MI/ACS; 30-day mortality |
LTS liberal transfusion strategy, RTS restrictive transfusion strategy, AMI acute myocardial infarction, MI myocardial infarction, ACS acute coronary syndrome, STE ST elevation, NSTE non-ST elevation, CAD coronary artery disease, CK creatinine kinase